Acquired resistance to cancer immunotherapy
Arianna Draghi1, Christopher Aled Chamberlain1, Andrew Furness2
1Center for Cancer Immune Therapy (CCIT), Department of Hematology, Herlev Hospital, University of Copenhagen, Herlev Ringvej 75, 2730, Herlev, Denmark.
Abstract:
In recent times, advances in cancer immunotherapy have yielded impressive, durable clinical responses in patients with varied subtypes of cancer. However, a significant proportion of patients who initially demonstrate encouraging tumor regression develop resistance and progress over time. The identification of novel therapeutic approaches to overcome resistance may result in significantly improved clinical outcomes and remains an area of high scientific priority. This review aims to summarize the current knowledge regarding the role of both tumor-intrinsic and tumor-extrinsic factors in the development of resistance to cancer immunotherapy and to discuss current and possible future therapeutic strategies targeting these mechanisms.
Insights
Cancer immunotherapy shows promise, but resistance is a challenge. This review explores tumor factors and strategies to overcome immunotherapy resistance for better patient outcomes.
Area of Science:
- Oncology
- Immunology
- Cancer Research
Background:
- Cancer immunotherapy has achieved significant clinical success in various cancer types.
- However, many patients develop resistance to these treatments, leading to disease progression.
Purpose of the Study:
- To review the current understanding of tumor-intrinsic and tumor-extrinsic factors contributing to cancer immunotherapy resistance.
- To discuss existing and potential therapeutic strategies to overcome this resistance.
Main Methods:
- Literature review of recent advances in cancer immunotherapy resistance.
- Synthesis of knowledge on mechanisms of resistance.
- Analysis of therapeutic strategies targeting resistance pathways.
Main Results:
- Identified key tumor-intrinsic factors (e.g., genetic mutations, tumor microenvironment) influencing immunotherapy response.
- Highlighted crucial tumor-extrinsic factors (e.g., systemic immunity, microbiome) impacting treatment efficacy.
- Summarized current therapeutic approaches and future directions for overcoming resistance.
Conclusions:
- Understanding the multifaceted nature of resistance is critical for improving immunotherapy efficacy.
- Targeting both tumor-intrinsic and extrinsic factors offers promising avenues for novel therapeutic development.
- Overcoming resistance is a high scientific priority to enhance clinical outcomes in cancer patients.
More Related Videos
Related Concept Videos
Treatment Resistant Cancers
Tumor Immunotherapy
Resistivity
Resistance
Equivalent Resistance
Resistance and Conductance
Various factors impact the resistance of a conductor. Spiraling in stranded conductors increases their...


